Lai Sicen, Xu Licong, Zhang Liang, Peng Lanyuan, Li Yixin, Liu Yuancheng, Yu Nianzhou, Chen Wangqing, Huang Kai
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, China.
Front Pharmacol. 2023 Mar 22;14:1141075. doi: 10.3389/fphar.2023.1141075. eCollection 2023.
Inhibitors of programmed cell death protein 1 and its associated ligand (PD-L1) are widely used in cancer treatment. However, medical costs and benefits of PD-1/PD-L1 inhibitors need attention owing to differences in response rates among individuals. This study explored global trends in the health economics field of PD-1/PD-L1 inhibitors to enhance their worldwide development. Bibliometric analysis of all documents currently indexed in Web of Science Core Collection from inception to 2022 was performed. Publication year, authors, countries, institutes, and journals were analyzed by Bibliometrix package (version 3.2.1) in R (version 4.1.3). CiteSpace (version 6.1.R6) and VOSviewer (version 1.6.18) were used to analyze burst words, co-authorship of institutes, co-cited journals, and co-cited references, while figures were mainly drawn by Ggplot2 package (version 3.3.5) in R (version 4.1.3) and SCImago Graphica Beta (version 1.0.23). A total of 2020 documents related to the health economics of PD-1/PD-L1 inhibitors were identified, and 1,204 documents met the selection criteria for inclusion in the study. A rapid increase in the number of publications since 2019 was observed, but this increase stopped in 2022, revealing research saturation in the field. (166 publications, 13.79% of total documents) had the most publications, while (2,890 co-citations) was the most co-cited journal. The United States was the leading contributor in this field with 506 publications and the top two productive institutes globally. The main hot topics included the cost-effectiveness of treatment with PD-1 and/or PD-L1 inhibitors, and the comparison between the cost-effectiveness of PD-/PD-L1 inhibitors and other drugs. There were substantial differences between developed and developing countries in the health economics field of PD-1 and/or PD-L1 inhibitors. The cost-effectiveness analysis of combined treatment with PD-1/PD-L1 inhibitors and other drugs warrants further attention. Findings from this study may provide governments and pharmaceutical companies with a strong reference for future research.
程序性细胞死亡蛋白1及其相关配体（PD-L1）抑制剂在癌症治疗中被广泛应用。然而，由于个体反应率存在差异，PD-1/PD-L1抑制剂的医疗成本和效益值得关注。本研究探讨了PD-1/PD-L1抑制剂健康经济学领域的全球趋势，以促进其在全球范围内的发展。对Web of Science核心合集中从创刊到2022年索引的所有文献进行了文献计量分析。使用R（版本4.1.3）中的Bibliometrix包（版本3.2.1）分析出版年份、作者、国家、机构和期刊。使用CiteSpace（版本6.1.R6）和VOSviewer（版本1.6.18）分析突发词、机构共同作者、共被引期刊和共被引参考文献，而图表主要由R（版本4.1.3）中的Ggplot2包（版本3.3.5）和SCImago Graphica Beta（版本1.0.23）绘制。共识别出2020篇与PD-1/PD-L1抑制剂健康经济学相关的文献，其中1204篇文献符合纳入本研究的选择标准。观察到自2019年以来出版物数量迅速增加，但这种增加在2022年停止，表明该领域研究已饱和。（166篇出版物，占文献总数的13.79%）的出版物数量最多，而（2890次共被引）是共被引次数最多的期刊。美国是该领域的主要贡献者，有506篇出版物，全球排名前两位的高产机构也在美国。主要热点话题包括PD-1和/或PD-L1抑制剂治疗的成本效益，以及PD-/PD-L1抑制剂与其他药物成本效益的比较。在PD-1和/或PD-L1抑制剂的健康经济学领域，发达国家和发展中国家之间存在很大差异。PD-1/PD-L1抑制剂与其他药物联合治疗的成本效益分析值得进一步关注。本研究结果可为政府和制药公司未来的研究提供有力参考。
